Heather Powell1, Peter G Gibson. 1. Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, Locked Bag 1, Hunter Mail Centre, Newcastle, NSW 2310, Australia. heather.powell@hunter.health.nsw.gov.au
Abstract
OBJECTIVE: To define the evidence for doses of inhaled corticosteroids in asthma and describe this in clinically meaningful, evidence-based terms. DATA SOURCE: Cochrane Database of Systematic Reviews. STUDY SELECTION AND DATA EXTRACTION: We identified systematic reviews of randomised controlled trials of dosing of inhaled corticosteroids in asthma. Data on efficacy and safety of different doses were extracted from meta-analyses and summarised as the number needed to treat (NNT) and number needed to harm (NNH). DATA SYNTHESIS: Inhaled corticosteroids were highly efficacious, with a relatively flat dose-response curve. Three patients needed to be treated with fluticasone 100 microg daily to prevent worsening asthma (NNT 3), and for fluticasone 1000 microg the NNT was 2.1 patients. The dose-response curve for side effects was steep. For a dose of fluticasone 100 microg, oral candidiasis developed in one of every 90 subjects treated (NNH 90). In contrast, the NNH for fluticasone 1000 microg and 2000 microg daily were 23 and 6, respectively. CONCLUSION: Level 1 evidence supports the use of low-dose inhaled corticosteroids in asthma. Clinicians should review doses of inhaled corticosteroids used for treating patients with asthma.
OBJECTIVE: To define the evidence for doses of inhaled corticosteroids in asthma and describe this in clinically meaningful, evidence-based terms. DATA SOURCE: Cochrane Database of Systematic Reviews. STUDY SELECTION AND DATA EXTRACTION: We identified systematic reviews of randomised controlled trials of dosing of inhaled corticosteroids in asthma. Data on efficacy and safety of different doses were extracted from meta-analyses and summarised as the number needed to treat (NNT) and number needed to harm (NNH). DATA SYNTHESIS: Inhaled corticosteroids were highly efficacious, with a relatively flat dose-response curve. Three patients needed to be treated with fluticasone 100 microg daily to prevent worsening asthma (NNT 3), and for fluticasone 1000 microg the NNT was 2.1 patients. The dose-response curve for side effects was steep. For a dose of fluticasone 100 microg, oral candidiasis developed in one of every 90 subjects treated (NNH 90). In contrast, the NNH for fluticasone 1000 microg and 2000 microg daily were 23 and 6, respectively. CONCLUSION: Level 1 evidence supports the use of low-dose inhaled corticosteroids in asthma. Clinicians should review doses of inhaled corticosteroids used for treating patients with asthma.
Authors: Mohamed S Al-Moamary; Sami A Alhaider; Abdullah A Alangari; Mohammed O Al Ghobain; Mohammed O Zeitouni; Majdy M Idrees; Abdullah F Alanazi; Adel S Al-Harbi; Abdullah A Yousef; Hassan S Alorainy; Mohamed S Al-Hajjaj Journal: Ann Thorac Med Date: 2019 Jan-Mar Impact factor: 2.219
Authors: Michael R Gionfriddo; John B Hagan; Christina R Hagan; Gerald W Volcheck; Ana Castaneda-Guarderas; Matthew A Rank Journal: Allergy Asthma Proc Date: 2015 Jul-Aug Impact factor: 2.587
Authors: Mohamed S Al-Moamary; Mohamed S Al-Hajjaj; Majdy M Idrees; Mohamed O Zeitouni; Mohammed O Alanezi; Hamdan H Al-Jahdali; Maha Al Dabbagh Journal: Ann Thorac Med Date: 2009-10 Impact factor: 2.219
Authors: Mohamed S Al-Moamary; Sami A Alhaider; Mohamed S Al-Hajjaj; Mohammed O Al-Ghobain; Majdy M Idrees; Mohammed O Zeitouni; Adel S Al-Harbi; Maha M Al Dabbagh; Hussain Al-Matar; Hassan S Alorainy Journal: Ann Thorac Med Date: 2012-10 Impact factor: 2.219